comparing surgery with tamoxifen did not find a difference in survival between the two groups but locoregional control led to a better result in the surgically treated patients. This led to the conclusion that optimum treatment for elderly patients could include both surgery and tamoxifen. A randomised study (Bates et al., 1991) compared tamoxifen only with optimal surgery followed by adjuvant tamoxifen. The overall survival after 3 years was similar between the two groups but a statistically significant higher locoregional relapse rate was reported in the group treated by tamoxifen only.
Breast cancer is the most common malignancy occurring in women. The incidence increases with age and approximately 30% of all new breast tumours occur in women over 70 years of age (Silverberg et al., 1988; Decarli et al., 1989) .
Guidelines for treating elderly patients are controversial since co-morbid conditions and poor functional status do not allow the application of clinical trials conducted in a younger population. At present, there is no consensus on the optimal treatment for breast cancer in this age group. Data from the literature (Bradbeer et al., 1983; Allan et al., 1985; Cummings et al., 1985; Margolese et al., 1989) suggest the use of tamoxifen either as primary treatment or as adjuvant therapy following surgery. Horobin et al. (1991) treated 113 patients over the age of 70 years with tamoxifen alone. These patients were followed for a minimum of 5 years and 60% failed to respond, with a high number of cases requiring a second-line treatment. Two randomised trials (Gazet et al., 1988; Robertson et al., 1988) comparing surgery with tamoxifen did not find a difference in survival between the two groups but locoregional control led to a better result in the surgically treated patients. This led to the conclusion that optimum treatment for elderly patients could include both surgery and tamoxifen. A randomised study (Bates et al., 1991) compared tamoxifen only with optimal surgery followed by adjuvant tamoxifen. The overall survival after 3 years was similar between the two groups but a statistically significant higher locoregional relapse rate was reported in the group treated by tamoxifen only.
The rationale of the present study was that non-randomised clinical studies (Helleberg et al., 1982; Preece et al., 1982; Allan et al., 1985) showed that tamoxifen as first-line treatment was of value in a selected group of elderly breast cancer patients. The question was whether surgery without axillary dissection combined with tamoxifen in patients with breast cancer and without clinical nodal involvement could give the same results in terms of overall survival, disease-free survival and quality of life compared with more radical treatments.
In a previous paper (Martelli et al., 1993) (Hermanek et al., 1987) , 77 (24%) a T2, 1 (0.3%) a T3 and 24 patients (7.5%) presented with a tumour infiltrating the skin but not the underlying muscle (T4b). All patients had surgery performed under local anaesthesia without axillary dissection; 298 underwent wide lumpectomy or quadrantectomy and 23 total mastectomy. The conservative surgical techniques have been previously described (Veronesi et al., 1990; Galante et al., 1992) .
All patients underwent resection of the tumour with removal of at least 2 cm of normal tissue to ensure a specimen with tumour-free margins. Patients with the margins of resection in tumour tissue were excluded from the analysis, since they were candidates for a re-excision or radiotherapy.
Independent of hormone receptor status, all patients received indefinitely 20 mg tamoxifen daily from the time of surgery. Tumour specimens were assayed for both oestrogen receptor (ER) and progesterone receptor (PgR) levels by using the dextran-coated charcoal Scatchard analysis. Patients with synchronous bilateral carcinomas or treated for previous malignant tumours were excluded from the analysis.
The product-limit method (Kaplan and Meier, 1958 ) was used to estimate relapse free-survival curves. Local recurrence, axillary and distant metastases were considered separately in the analysis. Since these events were not independent, a competing risk approach was used (Kalbfleish and Prentice, 1980) . For each event the crude cumulative incidence curves were obtained using a program developed by Abbattista et al. (1992) .
Resvlts
The predominant histological type was infiltrating ductal carcinoma (63.3%) and invasive lobular carcinoma accounted for 19% of the cases. ER and PgR content was determined in 267 patients. Of these, there were 239 patients (89.5%) who were ER', 190 (71.2%) who were PgR+ and 183 (69%) who were positive to both tumour receptors. Overall, 92.1% of the patients were receptor positive (ER or PgR) and 21 patients (7.9%) were ER-and PgR- (Table I) .
Local failure in the breast occurred in 17 patients at a median time from initial surgery of 33 months (range 9-101). The crude cumulative incidence of local relapse at 5 and 10 years from surgery was estimated to be 5. 4% and 8.7% respectively. In the TI group the local relapse rate at 72 months was 5.4% (12/219 patients). In all patients it was possible to remove the tumour relapse with a new wide resection. Four patients died from progression of disease, one from a second primary and three from causes not related to breast cancer.
Fourteen patients developed ipsilateral axillary recurrence at a median time of 32 months (range 8-69) from surgery. The crude cumulative incidence at 5 and 10 years was estimated to be 4.3% and 5.9% respectively. In the TI group the axillary recurrence rate at 72 months was 4.1% (9/219 patients). Eight patients were managed with radiotherapy, five with axillary dissection and one patient had both treatments. Four patients subsequently had further progression and died from disease and one patient from unrelated conditions. Twenty-three patients developed disseminated disease at a median time of 38 months (range 7-108) from initial surgery. The crude cumulative incidence of distant mtastascs at 5 and 10 years was estimated to be 6.2% and 13.4% respectively. Fifteen patients were treated with a second-line hormonal treatment, four patients with radiotherapy only and four patients had both treatments. Twentyone patients died from disease.
Five patients experienced new primary ipsilateral tumour and five contralateral breast carcinoma. The median time from initial surgery was 22 months (8-64 months) for ipsilateral tumour and 25 months (6-39 months) for contralateral tumour. All patients with ipsilateral tumour were treated with total mastectomy whereas wide resection was performed on the five patients with contralateral breast cancer.
Second primary tumours occurred in 13 patients (seven bowel cancers, three gastric cancers, one renal cancer, one vulvar cancer and one endometrial cancer) at a median time from surgery of 37 months (23-127 months).
Total mastectomy was performed only in patients with a larg tumour size (>3 cm) and with a concomitant very small breast. The association of these two factors, large tumour size and small breast, enabled us to perform surgery under local anaesthesia without any complication and with patients discharged on the day of surgery.
The distribution of site of recurre in relationship to tumour size and ER and PgR status is shown in Table II . Figure 1 shows the crude cumulative incidence of local, axillary and distant relapse as a function of time on the total series, and Figure 2 on 219 TI tumours. Two hundred and forty-four patients did not have any recurrence and 83 (25.8%) died from diseases not related to breast cancer. Cardiovascular diseases were the most common cause of death. The overall 72 month relapse-free survival rate was 76% with a 95% confidence interval (0.75-0.89) (Figure 3 ).
The data reported here seem to confirm that a strategy consisting in breast conservative surgery and adjuvant tamoxifen may yield results in terms of locoregional relapse rate equivalent to those obtained with more radical surgical approaches (Robertson et al., 1992) . The critical issue is whether axillary dissection may be safely omitted in elderly patients with primary breast cancer and clinically negative axillary nodes.
A randomised clinical trial (Fisher et al., 1985) compared, in patients with breast cancer and clnically negative axillary nodes, radical mastectomy with total mastectomy plus delayed axillary dissection only if nodes became clinically involved. The results at 10 years showed that of the 40% of patients in the group without axillary dissection expected to Surgy wbsd axEy dc5o -pamnbozl i edely hrn ra p-u*s (Gazet et al., 1988; Robertson et al., 1988; Bates et al., 1991) showed that pimary tamoxifen was inadequate to control locoregional disease in more than 40% of the cases. We believe that only patients unfit for surgery or who deine a surgical intervention may be treated by tamoxifen alone as first-line treatment. Cinical evidence from randomised trials suggests that there is an inreased risk of women developing endometrial cancer if tamoxifen is taken at a dose of 20 mg daily for long periods (Nayfield et al., 1991; Catherino et al., 1993) . In this study we did not observe an ieased risk of endometrial or other types of second ancers related to this age group. Only one woman experienced an endometrial cancer 52 months after breast surgery. We point out that no patient in follow-up had a rouine periodical gynaecological assesment such as pevic ultrasonography or hysteroscopy.
Given the role of surgery as primary therapy another issue has to be addressed. Is wide lumpectomy alone adequate therapy or should radiotherapy be administered after breastpreserving surgery? A recent controlled clinical trial (Veronesi et al., 1993) has challenged the usefulss of post-surgical radiotherapy in post-menopausal patients treated with conservative surgery. That study compared quadrantectomy vs quadrantectomy plus radiotherapy in patients with breast cancer size<2.5cm. and showed, in patients older than 55 years, a local relapse rate of 3.8% in the group without radiotherapy after a median follow-up of 39 months. The results of this study are similar to those of the present paper where, with a median follow-up of 67 months, the local relapse rate after conservative surgery and tamoxifen was 5.3%. The data of these two reports suggests that conservative surgery alone in post-menopausal patients with TI breast cancer may yield an acceptable local control. Other studies (Gazet et al., 1988; Reed et al., 1989; Bates et al., 1991; Fisher et al., 1991) The best way to resolve the issue of whether elderly patients with TI breast cancer and without clinical axillary involvement should be recommended surgery with or without axillary dissection would be a randomised prospective trial. Such a trial would have the aim of verifying the necessity of axillary dissection and the impact on disease-free survival.
In conclusion, the treatment of early stage breast ancer in elderly patients has to be re-evaluated in the near future, perhaps resticting axillary node dissection to those patients with chnically involved nodes.
